New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
07:19 EDTINCYIncyte data positive, says Oppenheimer
After Incyte reported results for ruxolitinib in pancreatic cancer, Oppenheimer thinks the data supports the evaluation of ruxolitinib in a wide range of tumor types. Following the results of an IDO + ipilimumab proof-of-concept study in melanoma, Oppenheimer finds the results encouraging. The firm keeps a $75 price target on the shares and reiterates an Outperform rating.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 2, 2015
07:31 EDTINCYIncyte to present new data on immuno-oncology portfolio at SITC
Subscribe for More Information
October 1, 2015
07:31 EDTINCYLeerink to hold a roundtable
Subscribe for More Information
September 30, 2015
08:30 EDTINCYIncyte to join Nasdaq-100 Index beginning Oct. 7, to replace Altera
Nasdaq yesterday announced that Incyte Corporation (INCY), will become a component of the NASDAQ-100 Index and the NASDAQ-100 Equal Weighted Index prior to market open on Wednesday, October 7, 2015. Incyte Corporation will replace Altera Corporation (ALTR). Incyte Corporation is headquartered in Palo Alto, California, and has a market capitalization of approximately $19B.
September 29, 2015
06:47 EDTINCYEli Lilly and Incyte's baricitinib Phase 3 study met primary objective
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use